|Generate QR code
Open Access
Subscription Access
Analysis of the association of the polymorphic locus rs17878362 of the TP53 gene with the risk of ovarian cancer
https://doi.org/10.25557/2073-7998.2022.07.63-65
Abstract
Among malignant neoplasms of the organs of the female reproductive system, ovarian cancer (OC) leads in the number of deaths. The molecular mechanism of ovarian tumor development contains a variety of genetic and epigenetic events that cause activation of oncogenes and inactivation of tumor suppressor genes underlying malignant cell transformation [2]. The TP53 gene is one of the tumor suppressor genes. Violation or insufficient functioning of the protein product of this gene leads to the development of various oncological diseases, including ovarian cancer. This paper presents an associative analysis of the variant rs17878362 of the TP53 gene with the risk of ovarian cancer in women from the Republic of Bashkortostan.
About the Authors
A. V. Korosteleva
Bashkir State University
Russian Federation
Russian Federation
O. K. Kharina
Bashkir State University
Russian Federation
Russian Federation
E. T. Mingazheva
Bashkir State University
Russian Federation
Russian Federation
Ya. V. Valova
Bashkir State University; Ufa Research Institute of Occupational Health and Human Ecology
Russian Federation
Russian Federation
E. A. Andreeva
Bashkir State University
Russian Federation
Russian Federation
D. S. Prokofyeva
Bashkir State University
Russian Federation
Russian Federation
E. K. Khusnutdinova
Institute of Biochemistry and Genetics - Subdivision of the Ufa Federal Research Centre of the Russian Academy of Sciences
Russian Federation
Russian Federation
References
1. Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена, филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2021. 252 с.
2. Zhang Y., Cao L., Nguyen D., Lu H. TP53 mutations in epithelial ovarian cancer. Translational Cancer Research. 2016 Dec; 5(6): 650-663.
3. Aubrey B.J., Strasser A., Kelly G.L. Tumor-Suppressor Functions of the TP53 Pathway. Cold Spring Harb Perspect Med. 2016 May; 6(5): a026062.
4. Eskandari-Nasab E., Hashemi M., Amininia S., Ebrahimi M., Rezaei M., Mehdi Hashemi S. Effect of TP53 16-bp and β-TrCP 9-bp INS/DEL polymorphisms in relation to risk of breast cancer. Gene. 2015 Sep; 568(2): 181-5.
5. Hao W., Xu X., Shi H., Zhang C., Chen X. No association of TP53 codon 72 and intron 3 16-bp duplication polymorphisms with breast cancer risk in Chinese Han women: new evidence from a population-based case-control investigation. European Journal of Medical Research. 2018 Oct; 23(1): 47.
6. Morten B., Chiu S., Oldmeadow C., Lubinski J., Scott R., Avery-Kiejda K. The intron 3 16 bp duplication polymorphism of p53 (rs17878362) is not associated with increased risk of developing triple-negative breast cancer. Breast Cancer Research and Treatment. 2019 Feb; 173(3): 727-733.
Review
For citations:
Korosteleva A.V., Kharina O.K., Mingazheva E.T., Valova Ya.V., Andreeva E.A., Prokofyeva D.S., Khusnutdinova E.K. Analysis of the association of the polymorphic locus rs17878362 of the TP53 gene with the risk of ovarian cancer. Medical Genetics. 2022;21(7):63-65. (In Russ.) https://doi.org/10.25557/2073-7998.2022.07.63-65
Views:
331
Email this article 